Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

C.S.E. Verbrugge; M.C.M. Al; Y.G. Assaraf; D. Niewerth; J. van Meerloo; J. Cloos; M.S. van der Veer; G.L. Scheffer; G.J. Peters; E.T. Chan; J.L. Anderl; C.J. Kirk; S. Zweegman; B.A.C. Dijkmans; W.F. Lems; R.J. Scheper; T.D. de Gruijl; G. Jansen

doi:10.1186/s40164-016-0032-7

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

C.S.E. Verbrugge, M.C.M. Al, Y.G. Assaraf, D. Niewerth, J. van Meerloo, J. Cloos, M.S. van der Veer, G.L. Scheffer, G.J. Peters, E.T. Chan, J.L. Anderl, C.J. Kirk, S. Zweegman, B.A.C. Dijkmans, W.F. Lems, R.J. Scheper, T.D. de Gruijl, G. Jansen

Research output: Contribution to journal › Article › Academic › peer-review

83 Downloads (Pure)

Original language	Undefined/Unknown
Article number	2
Journal	Experimental hematology & oncology
Volume	2
DOIs	https://doi.org/10.1186/s40164-016-0032-7
Publication status	Published - 2013

Access to Document

10.1186/s40164-016-0032-7

308420Final published version, 800 KB

http://dx.doi.org/10.1186/2162-3619-2-2

Cite this

Verbrugge, C. S. E., Al, M. C. M., Assaraf, Y. G., Niewerth, D., van Meerloo, J., Cloos, J., van der Veer, M. S., Scheffer, G. L., Peters, G. J., Chan, E. T., Anderl, J. L., Kirk, C. J., Zweegman, S., Dijkmans, B. A. C., Lems, W. F., Scheper, R. J., de Gruijl, T. D., & Jansen, G. (2013). Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Experimental hematology & oncology, 2, [2]. https://doi.org/10.1186/s40164-016-0032-7

@article{307725253c924f6e8939e85ee6409d90,

title = "Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors",

author = "C.S.E. Verbrugge and M.C.M. Al and Y.G. Assaraf and D. Niewerth and {van Meerloo}, J. and J. Cloos and {van der Veer}, M.S. and G.L. Scheffer and G.J. Peters and E.T. Chan and J.L. Anderl and C.J. Kirk and S. Zweegman and B.A.C. Dijkmans and W.F. Lems and R.J. Scheper and {de Gruijl}, T.D. and G. Jansen",

year = "2013",

doi = "10.1186/s40164-016-0032-7",

language = "Undefined/Unknown",

volume = "2",

journal = "Experimental hematology & oncology",

issn = "2162-3619",

publisher = "BioMed Central",

}

Verbrugge, CSE, Al, MCM, Assaraf, YG, Niewerth, D, van Meerloo, J, Cloos, J, van der Veer, MS, Scheffer, GL, Peters, GJ, Chan, ET, Anderl, JL, Kirk, CJ, Zweegman, S , Dijkmans, BAC , Lems, WF , Scheper, RJ , de Gruijl, TD & Jansen, G 2013, 'Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors', Experimental hematology & oncology, vol. 2, 2. https://doi.org/10.1186/s40164-016-0032-7

TY - JOUR

T1 - Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

AU - Verbrugge, C.S.E.

AU - Al, M.C.M.

AU - Assaraf, Y.G.

AU - Niewerth, D.

AU - van Meerloo, J.

AU - Cloos, J.

AU - van der Veer, M.S.

AU - Scheffer, G.L.

AU - Peters, G.J.

AU - Chan, E.T.

AU - Anderl, J.L.

AU - Kirk, C.J.

AU - Zweegman, S.

AU - Dijkmans, B.A.C.

AU - Lems, W.F.

AU - Scheper, R.J.

AU - de Gruijl, T.D.

AU - Jansen, G.

PY - 2013

Y1 - 2013

U2 - 10.1186/s40164-016-0032-7

DO - 10.1186/s40164-016-0032-7

M3 - Article

C2 - 26823993

SN - 2162-3619

VL - 2

JO - Experimental hematology & oncology

JF - Experimental hematology & oncology

M1 - 2

ER -